AMES, IA--(Marketwire - Oct 31, 2012) - NewLink Genetics Corporation ( NASDAQ : NLNK ), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today reported consolidated financial results for the third quarter of 2012. NewLink updated the status of its clinical development programs including its HyperAcute Pancreas Immunotherapy Phase 3 trial (Immunotherapy for Pancreatic Resectable cancer Survival Study or "IMPRESS").

"As we approach the trigger event for the first interim analysis in our IMPRESS pivotal study, we have continued to execute our plan within the financial guidance we provided at the beginning of this year," commented Dr. Charles Link, Chairman and Chief Executive Officer of NewLink.

"In addition to our IMPRESS pivotal study for resected pancreatic patients, we have initiated a separate Phase 3 study for patients with locally advanced disease," said Dr. Nicholas Vahanian, NewLink's President and Chief Medical Officer. "If approved this new indication potentially doubles the number of patients who could be treated with algenpantucel-L. We are also expanding our HyperAcute immunotherapy platform by opening a major Phase 2B/3 study in non-small cell lung cancer."

The third quarter 2012 Financial Results

Financial Guidance

NewLink expects to end 2012 with $20 million to $23 million in cash, cash equivalents and marketable securities.

Significant recent events:

Upcoming Activities

NewLink expects to present at the following investor conferences:

About NewLink Genetics Corporation

More here:
NewLink Genetics Corporation Reports Third Quarter 2012 Financial Results

Comments are closed.